Heterogeneity of Acquired Resistance Mechanisms to PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer and Clinical Strategies

Yachen Xiao

doi:10.54254/2753-8818/2026.PJ31457

Article Information

Received: 22 January 2026

Published: 26 January 2026

DOI: https://doi.org/10.54254/2753-8818/2026.PJ31457

Article Type: Research Article

Cite this article

Xiao,Y. (2026). Heterogeneity of Acquired Resistance Mechanisms to PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer and Clinical Strategies. Theoretical and Natural Science,157,46-52.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.157

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., et al. (2023). Lung cancer immunotherapy: Progress, pitfalls, and promises. Molecular Cancer, 22, 40.

[2]Mariniello, A., Borgeaud, M., Weiner, M., Frisone, D., Kim, F., & Addeo, A. (2025). Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: From bedside to bench and back. BioDrugs, 39, 215–235.

[3]Bell, H. N., & Zou, W. (2024). Beyond the barrier: Unraveling the mechanisms of immunotherapy resistance. Annual Review of Immunology, 42, 521–550.

[4]Miller, B. C., Choutri, Y., Abosy, R. A., Huang, A., Cox, E. K., Zimmerman, M. P., et al. (2023). Abstract 6362: Overcoming resistance to immunotherapy due to loss of antigen presentation. Cancer Research, 83, 6362.

[5]Ranjan, K., Rajendran, B. K., Deen, I. U., Costantini, A., de Rodas, M. L., Desai, S. S., et al. (2025). IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Molecular Cancer, 24, 80.

[6]Wong, C. W., Evangelou, C., Sefton, K. N., Leshem, R., Zhang, W., Gopalan, V., et al. (2023). PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models. Nature Communications, 14, 5983.

[7]Chen, B., Hu, J., Hu, X., Chen, H., Bao, R., Zhou, Y., et al. (2022). DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion. Nature Communications, 13, 2059.

[8]van de Haar, J., Mankor, J. M., Hummelink, K., Monkhorst, K., Smit, E. F., Wessels, L. F. A., et al. (2024). Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer. Clinical Cancer Research, 30, 1307–1318.

[9]Exposito, F., Redrado, M., Houry, M., Hastings, K., Molero-Abraham, M., Lozano, T., et al. (2023). PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells. Cancer Research, 83, 2513–2526.

[10]Boumelha, J., de Castro, A., Bah, N., Cha, H., de Carné Trécesson, S., Rana, S., et al. (2024). CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Cancer Research, 84, 2231–2246.

[11]Vanmeerbeek, I., Naulaerts, S., Sprooten, J., Laureano, R. S., Govaerts, J., Trotta, R., et al. (2024). Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy. Science Advances, 10, eadm8660.

[12]Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020). Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Frontiers in Immunology, 11, 783.

[13]Agarwala, Y., Brauns, T. A., Sluder, A. E., Poznansky, M. C., & Gemechu, Y. (2024). Targeting metabolic pathways to counter cancer immunotherapy resistance. Trends in Immunology, 45, 486–494.

[14]Chen, J., Zhao, D., Wang, Y., Liu, M., Zhang, Y., Feng, T., et al. (2024). Lactylated apolipoprotein C-II induces immunotherapy resistance by promoting extracellular lipolysis. Advanced Science, 11, e2406333.

[15]Wang, M., Wang, Y., Pan, X., Wang, B., Wang, Y., Luo, X., et al. (2025). Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer. Proceedings of the National Academy of Sciences, 122, e2500019122.

[16]Yen, Y.-T., Zhang, Z., Chen, A., Qiu, Y., Liu, Q., Wang, Q., et al. (2025). Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy. Journal of Nanobiotechnology, 23, 124.

[17]Yang, F., Akhtar, M. N., Zhang, D., El-Mayta, R., Shin, J., Dorsey, J. F., et al. (2024). An immunosuppressive vascular niche drives macrophage polarization and immunotherapy resistance in glioblastoma. Science Advances, 10, eadj4678.

[18]Chen, H. J. (2025). Breathing down resistance: Tackling hypoxia to overcome immunotherapy barriers in lung cancer. Journal of Experimental Medicine, 222, e20241581.

[19]Ren, D., Hua, Y., Yu, B., Ye, X., He, Z., Li, C., et al. (2020). Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Molecular Cancer, 19.

[20]Rother, C., John, T., & Wong, A. (2024). Biomarkers for immunotherapy resistance in non-small cell lung cancer. Frontiers in Oncology, 14, 1489977.

[21]Quek, C., Pratapa, A., Bai, X., Al-Eryani, G., Pires da Silva, I., Mayer, A., et al. (2024). Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy. Cell Reports, 43, 114392.

[22]Le, J., Dian, Y., Zhao, D., Guo, Z., Luo, Z., Chen, X., et al. (2025). Single-cell multi-omics in cancer immunotherapy: From tumor heterogeneity to personalized precision treatment. Molecular Cancer, 24, 221.

[23]Zhang, Z., Chen, X., Gao, S., Fang, X., & Ren, S. (2024). 3D bioprinted tumor model: A prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment. Cell Oncology (Dordrecht), 47, 1113–1126.

[24]Taleb, S., Phan, L., Cousin, S., Rouleau, E., Leroy, L., Soubeyran, I., et al. (2025). ctDNA features of acquired resistance to immunotherapy in advanced NSCLC. Journal of Clinical Oncology, 43, 2563.

[25]Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., et al. (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 560, 382–386.

[26]Tarin, M., Oryani, M. A., Javid, H., & Karimi-Shahri, M. (2025). Exosomal PD-L1 in non-small cell lung cancer: Implications for immune evasion and resistance to immunotherapy. International Immunopharmacology, 155, 114519.

[27]Keddar, M. R., Pro, S. C., Burke, K., Stewart, A. C., Cobbold, M., Stewart, R., et al. (2024). Abstract 5100: Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade. Cancer Research, 84, 5100.

[28]Harel, M., Christopoulos, P., Puzanov, I., Bar, J., Kamer, I., Reinmuth, N., et al. (2024). Abstract 1208: Plasma proteomics-based models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy. Cancer Research, 84, 1208.

[29]Chu, X., Tian, W., Wang, Z., Zhang, J., & Zhou, R. (2023). Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: Mechanisms and clinical trials. Molecular Cancer, 22, 93.

[30]Wang, Y., Xiao, L., Wu, F., Ren, B., Zhou, C., Hu, P., et al. (2025). Abstract 7301: FP011, a tri-specific immune checkpoint inhibitor targeting PD-1 × TIGIT × PVRIG for cancer immunotherapy. Cancer Research, 85, 7301.

[31]Cheng, W., Kang, K., Zhao, A., & Wu, Y. (2024). Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. Journal of Hematology & Oncology, 17, 54.